Molecule intelOpportunity: StrongEssential

Buprenorphine

42 brands · 35 companies · product forms

ATC: N02AE01, N07BC01 1 DRAP alert

Opportunity snapshot

Launch attractiveness
53
Market saturation
78
Price room
100
Regulatory risk
50
42
brands
35
companies
Rs 767.62
median price
10
price points
17.04x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 7%

Price room

Across observed sources and strengths
CheapestRs 66.44
MedianRs 767.62
Most expensiveRs 1,131.86
Spread17.04×
Sources: DRAP-official

max/min price ratio 17.04x across 10 trusted points (Rs 66.44-1131.86). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 8 live products for Buprenorphine — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2024-05-29
Voluntary Recall Alert: Drug Product; Cadlec 30mg/mL Injection by Brooks Pharma Pvt Ltd.,

Why this score

Launch attractiveness

40% supply-gap(45) + 25% price-variation(100) + 20% low-competition(22) + 15% supply-disruption(40), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

35 canonical companies and 42 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 17.04x across 10 trusted points (Rs 66.44-1131.86). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2024-05-29 incl. recall/safety.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.